Regeneron, Intellia Therapeutics expand research collaboration to make gene editing therapiesReuters • 10/03/23
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular DiseasesGlobeNewsWire • 10/03/23
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority ReviewGlobeNewsWire • 09/29/23
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023GlobeNewsWire • 09/28/23
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority ReviewGlobeNewsWire • 09/26/23
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing LossGlobeNewsWire • 09/25/23
Regeneron's pricing deal with federal government may have ‘far-reaching consequences,' analysts sayMarket Watch • 09/15/23
Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/11/23
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at 2023 Wells Fargo Healthcare Conference (Transcript)Seeking Alpha • 09/06/23
OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 StudyBusiness Wire • 09/06/23
DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTXBusiness Wire • 09/05/23